Physician profile
Michael S Cartwright
NPI 1417987827
$8,113.91
in general payments reported to CMS, 2019-2025
15 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $120 · 2021: $5,228 · 2022: $75.00 · 2023: $1,005 · 2024: $643 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Consulting Fee: $690 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175 · Education: $88.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.87 |
| Consulting Fee | $690.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175.00 |
| Education | $88.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $5,435.00 | 2020-2023 | |
| Genentech USA, INC. | $690.00 | 2023 | Evrysdi |
| Biogen, INC. | $634.61 | 2023-2025 | Spinraza, Qalsody, Skyclarys |
| Cadwell Industries, INC | $477.36 | 2019-2025 | |
| Ptc Therapeutics, INC. | $271.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $135.00 | 2025 | |
| Argenx US, INC. | $122.50 | 2025 | Vyvgart |
| Ns Pharma, INC. | $103.97 | 2023 | Viltepso |
| Csl Behring | $51.19 | 2019-2021 | |
| Amylyx Pharmaceuticals, INC. | $49.09 | 2024 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $44.59 | 2024 | |
| Alexion Pharmaceuticals, INC. | $39.09 | 2019-2024 | |
| Natus Medical Incorporated | $31.85 | 2019 | |
| Sarepta Therapeutics, INC. | $15.64 | 2023 | |
| Genzyme Corporation | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.